PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

PolyActiva is a Melbourne-based ophthalmology company developing a novel proprietary drug delivery platform. Today the company reported promising interim results from an ongoing Phase 2a clinical study for its PA5108 Ocular Implant in subjects with mild to moderate glaucoma. This ocular implant is…